New DrugDev Webinar: How and Why Novartis Made the Decision to Use eConsent on Global Clinical Trials

Share Article

Scott Askin of Novartis joins Karen Maduschke of DrugDev to reveal best practices, lessons learned, and European regulatory and IRB considerations when transitioning from paper to eConsent

Join the webinar 10 October, 1:00-2:00 BST | 2:00-3:00 CET

The live, educational webinar will discuss how and why Novartis made the switch to eConsent for clinical trials.

DrugDev, a QuintilesIMS company, will partner with Novartis to host a live educational webinar on 10 October 2017 discussing how and why Novartis made the decision to use eConsent on global clinical trials. The webinar will discuss best practices, lessons learned, and European regulatory and IRB considerations related to the transition from paper methods.

Webinar: Going Global with eConsent: The Novartis Journey – Lessons Learned
Date: 10 October 2017
Time: 8:00-9:00am ET | 1:00-2:00pm BST | 2:00-3:00 pm CET
Presenters:

  • Scott Askin, Global Director in Digital Development, Novartis
  • Karen Maduschke, Director of Training & Support, DrugDev

Registration: Register Here

Attendees will learn:

  • Why Novartis made the decision to use eConsent, challenges faced, and how they addressed those challenges
  • Key eConsent features, and benefits to Novartis
  • How eConsent meets the regulatory needs for European signatures and IRB requests

Electronic informed consent (eConsent) is a modern, intuitive and interactive delivery of consent-related materials that effectively informs and presents new opportunities to help patients and clinical sites worldwide. Friendly and intuitive features such as video, interim understanding acknowledgements, question flagging, and audio narration are consistently proven to increase patient satisfaction and comprehension. Studies have shown this to improve patient retention rates in addition to helping study teams ensure transparency, streamline documentation, and simplify monitoring.

About the Presenters
Scott Askin has over 15 years of experience in the pharma industry. He is a digital strategist, intrapeneur and recognized master of Data Management. Based in Basel, Switzerland, he is a member of the Novartis Digital elite, leading the company’s work in eSource and eICF/eConsent. Scott has a proven track record of success overcoming the “impossible” and bringing new technologies to fruition through identifying, testing and scaling digital solutions in close collaboration with internal and external stakeholders. Scott has a BSc (Hons) in Computing and Management Sciences from Sheffield Hallam University in the United Kingdom.

Karen Maduschke’s expertise in electronic consent systems for the global healthcare industry evolves from a background in health and intercultural communication merged with more than 20 years of industry experience, focused mostly on digital communication in multinational settings. A fierce advocate for patient-centricity in clinical trials, she currently leads the patient education and training and support teams for DrugDev. Based near Dusseldorf, Germany, Karen holds a Master of Arts in Communication from Michigan State University in the United States. She also completed four years of doctoral research in cross-cultural physician-patient communication.

About DrugDev
DrugDev, a QuintilesIMS company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty
DrugDev
+1 617.688.3253
Email >

Cynthia Murray
DrugDev
888.650.1860
Email >
@drugdevinc
Follow >
Visit website